# A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.

> **NCT07016997** · PHASE1 · RECRUITING · sponsor: **Chiome Bioscience Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Solid Tumors
- Refractory Cancer

## Interventions

- **DRUG:** CBA-1535
- **DRUG:** CBA-1535+Pembrolizumab

## Key facts

- **NCT ID:** NCT07016997
- **Lead sponsor:** Chiome Bioscience Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-27
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07016997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07016997, "A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07016997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*